Company

Clarity Pharmaceuticals Ltd

Headquarters: Sydney, NSW, Australia

Employees: 41

CEO: Dr. Colin David Biggin Ph.D.

ASX: CU6 -1.49%

Detailed Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Clarity Pharmaceuticals Ltd has the following listings and related stock indices.


Stock: ASX: CU6 wb_incandescent

Details

Headquarters:

National Innovation Centre

Sydney, NSW 2015

Australia

Phone: 61 2 9209 4037